The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs
The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs
Hepatitis C virus (HCV) infection is easy to chronic and can progress to cirrhosis and liver
 cancer. Direct-acting antiviral treatment can significantly improve the prognosis of the
 disease and the efficacy is seemingly not affected by a variety of viral factors. In
 addition, direct-acting antiviral agents therapy may affect the transformation of the immune
 cells and ameliorate the host immune status consequently. This study mainly investigated the
 relationship between Direct Acting Antiviral Treatment effect and the functional activity of
 myeloid-derived suppressor cells (MDSCs) and natural killer cells (NK cells) in Chronic
 Hepatitis C.
32 treatment-naive CHC patients and 20 healthy controls were recruited. Patients were
 examined before DAAs therapy (0w) and at weeks 4 (4w) and weeks 12 (12w) and weeks24 (24w) of
 the therapy. The percent age of myeloid-derived suppressor cells and NK cells of the
 peripheral blood were analyzed by flow cytometry. The investigators discuss the relationship
 between direct acting antiviral treatment effect and myeloid-derived suppressor cells and NK
 cells activity in chronic hepatitis C.
Inclusion Criteria:

 -  Positive serum Anti-HCV antibody or serum HCV-RNA, CHC patients without any treatment

 Exclusion Criteria:

 -  Patient has a history of clinical signs/symptoms of hepatic decompensation (Child-Pugh
 Grade B or C) or ascites, esophageal variceal bleeding, hepatic encephalopathy, or
 spontaneous bacterial peritonitis.

 -  Patient has a history of hepatocellular carcinoma (HCC) or suspected symptoms of HCC,
 such as suspicious foci on imaging studies and/or serum alpha-fetoprotein
 (AFP)>50ng/mL.

 -  Patient has received IFN or other immunomodulatory treatment within 52 weeks before
 Screening.

 Patient has a medical condition that requires frequent use of systemic acyclovir or
 famciclovir.

 -  Patient has a medical condition that requires frequent use of systemic
 corticosteroids, however topical and inhaled corticosteroids are allowed.

 Patient has used hepatotoxic drugs within one month. Patient has overtaken alcohol
 (>40g/day) or abused illicit drugs in recent one year.

 -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
 female after conception and until the termination of gestation, confirmed by a
 positive urine pregnancy test.

 -  Patients who co-infected with HAV, HBV, HDV, HEV,HIV(human immunodeficiency virus )
 Patient has one or more additional known primary or secondary causes of liver disease,
 other than hepatitis C (e.g., alcoholism, autoimmune hepatitis).

 History of malignancy of any organ system.